Nature and modes of action of probiotics in intestinal infections

Antibiotiques

Volumn 5, Issue 2, 2003, Pages 107-113

  De Vecchi, E ^a   Gismondo, M R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Diarrhoea; Intestinal infections; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; PROBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; DIARRHEA; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE INFECTION; LACTOBACILLUS CASEI; MEDICAL LITERATURE; MICROBIAL ADHESION; NONHUMAN; NUTRIENT; PATHOGENESIS; PH MEASUREMENT; REVIEW; SACCHAROMYCES BOULARDII; TRAVELLER DIARRHEA;

EID: 0038296226     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. METCHNIKOFF E. The prolongation of life. Optimistic studies. London: Butterworth-Heinemann, 1907.
2. LILLY DM, STILLWELL RH. Probiotics. Growth promoting factors produced by micro-organisms. Science 1965 ; 147 : 747-8.
3. PARKER RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health 1974 ; 29 : 4-8.
4. FULLER R. Probiotics in man and animals. J Appl Bacteriol 1989 ; 66 : 365-78.
5. SCHREZENMEIR J, DE VRESE M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001 ; 73 (Suppl) : 361S-4S.
6. ALVAREZ-OLMOS MI, OBERHELMAN RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001 ; 32 : 1567-76.
7. LEWIS SJ, FREEDMAN AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998 ; 12 : 807-12.
8. GISMONDO MR, DRAGO L, LOMBARDI A. Review of probiotics available to modify gastrointestinal flora. Int J Antimicrob Agents 1999 ; 12 : 287-92.
9. OUWEHAND AC, SALMINEN S, ISOLAURI E. Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 2002 ; 82 : 279-89.
10. SULLIVAN Å, NORD CE. The place of probiotics in human intestinal infections. Int J Antimicrob Agents 2002 ; 20 : 313-9.
11. ELMER GW, McFARLAND LV. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001 ; 30 : 837-54.
12. HOLZAPFEL WH, HABERER P, SNEL J, et al. Overview of gut flora and probiotics. Int J Food Microbiol 1998 ; 41 : 85-101.
13. PERITI P, TONELLI F. Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii. J Chemother 2001 ; 13 : 473-93.
14. REID G, BURTON J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 2002 ; 4 : 319-24.
15. VANDERHOOF JA, YOUNG R. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr 1998 ; 27 : 323-32.
16. ISOLAURI E, SUTAS Y, KANKAANPAA P, et al. Probiotics: effects on immunity. Am J Clin Nutr 2001 ; 73 (Suppl) : 444S-50S.
17. MARTEAU PR, DE VRESE M, CELLIER JC, et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001 ; 73 (Suppl) : 430S-6S.
18. DE VRESE M, SCHREZENMEIR J. Probiotics and non intestinal infectious conditions. Br J Nutr 2002 ; 88 (Suppl 1) : 59-66.
19. DE ROOS NM, KATAN MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000 ; 71 : 405-11.
20. ISOLAURI E. Probiotics in human disease. Am J Clin Nutr 2001 ; 73 (Suppl) : 1142S-6S.
21. BERG RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996 ; 4 : 430-5.
22. MOROTOMI M, WATANABE T, SUEGARA N, et al. Distribution of indigenous bacteria in the digestive tract of conventional and gnotobiotics rats. Infect Immun 1975 ; 11 : 962-8.
23. FINEGOLD SM, ATTEBERY HR, SUTER VL. Effect of diet on human fecal flora: comparison of Japanese and American diets. Am J Clin Nutr 1974 ; 27 : 1456-69.
24. BENGMARK S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut 1998 ; 42 : 2-7.
25. SAVAGE DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1997 ; 31 : 107-33.
26. MCFARLAND LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Diagn Dis 1998 ; 16 : 292-307.
27. BARTLETT JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992 ; 15 : 573-81.
28. NORD CE, HEIMDAL A, KARGER L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986 ; 49 : 64-72.
29. BERGOGNE-BÉRÉZIN E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 2000 ; 16 : 521-6.
30. HOGENAUER C, HAMMER HF, KREJS GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998 ; 27 : 702-10.
31. MCFARLAND LV, MULLIGAN ME, KWOK RY, et al.. Nosocomial acquisition of Clostridium difficile infection. N Engl J Mcd 1989 ; 320 : 204-10.
32. FEKETY R, SHAH AB. Diagnosis and treatment of Clostridium difficile colitis. J Am Med Assoc 1993 ; 269 : 71-5.
33. SURAWICZ CM, MCFARLAND LV. Pseudomembraneous colitis: causes and cures. Digestion 1999 ; 60 : 91-100.
34. GUANDALINI S. The treatment of acute diarrhea in the third millenium: a pediatrician's perspective. Acta Gastroenterol Belg 2002 ; 65 : 33-6.
35. WALKER-SMITH JA Post-infective diarrhoea. Curr Opin Infect Dis 2001 ; 14 : 567-71.
36. SLOTWINER-NIE PK, BRANDT LJ. Infectious diarrhea in the elderly. Gastroenterol Clin North Am 2001 ; 30 : 625-35.
37. MAJAMAA H, ISOLAURI E, SAXELIN M, et al. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995 ; 20 : 333-8.
38. COFFIN SE. Rotavirus vaccines: current controversies and future directions. Curr Infect Dis Rep 2000 ; 2 : 78-83.
39. SALIM AF, PHILLIPS AD, FARTHING MJ. Pathogenesis of gut virus infection. Baillières Clin Gastroenterol 1990 ; 4 : 593-607.
40. DE LAS CASAS C, ADACHI J, DUPONT H. Review article: travellers' diarrhea. Aliment Pharmacol Ther 1999 ; 13 : 1373-8.
41. FELDMAN M. Southwestern internal medicine conference. Traveller's diarrhea. Am J Med Sci 1984 ; 288 : 136-48.
42. HOGE CW, SHLIM DR, RAJAH R, et al. Epidemiology of diarrhoeal illness associated with coccidian-like organisms among travellers and foreign residents in Nepal. Lancet 1993 ; 341 : 1175-9.
43. SAARELA M, LAHTEENMAKI L, CRITTENDEN R, et al. Gut bacteria and health foods-the European perspective. Int J Food Microbiol 2002 ; 78 : 99-117.
44. HELANDER I, VON WRIGHT A, MATTILA-SAND-HOLM T. Potential of lactic acid bacteria and novel antibacterials against gram-negative bacteria. Trends Food Sci Technol 1997 ; 8 : 146-50.
45. NIKU-PAAVOLA ML, LATVA-KALA K, LAITILA A, et al. New types of antimicrobial compounds produced by Lactobacillus plantarum. J Appl Microbiol 1999 ; 86 : 9-35.
46. SILVA M, JACOBUS NV, DENEKE C, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987 ; 31 : 1231-3.
47. GORBACH SL. The discovery of Lactobacillus GG. Nutr Today 1996 ; 31 (Suppl 6) : S2-S4.
48. LIÉVIN-LE MOAL V, AMSELLEM R, ERVIN AL, et al. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut 2002 ; 50 : 803-11.
49. BERNET-CAMARD MF, LIÉVIN V, BRASSART D, et al. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance (s) active in vitro and in vivo. Appl Environ Microbiol 1997 ; 63 : 2747-53.
50. FORESTIER C, DE CHAMPS C, VATOUX C, et al. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 2001 ; 152 : 167-73.
51. PEREZ PF, MINNARD J, ROUVET M, et al. Inhibition of Giardia intestinalis by extracellular factors from Lactobacilli: an in vitro study. Appl Environ Microbiol 2001; 67: 5037.
52. LIÉVIN V, PEIFFER I, HUDAULT S, et al. Bifido-bacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000 ; 47 : 646-52.
53. COCONNIER MH, LIÉVIN V, BERNET-CAMARD MF, et al. Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob Agents Chemother 1997 ; 41 : 1046-52.
54. OGAWA M, SHIMIZU K, NOMOTO K, et al. Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157: H7 by probiotic Lactobacillus strains due to production of lactic acid. Int J Food Microbiol 2001 ; 68 : 135-40.
55. MANGELL P, NEJDFORS P, WANG M et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci 2002 ; 47 : 511-6.
56. EKLUND T. The antimicrobial effect of dissociated and undissociated sorbic acid at different pH levels. J Appl Bacteriol 1983 ; 54 : 383-9.
57. VANDENBERGH PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993 ; 12 : 221-38
58. CHERRINGTON CA, HINTON M, CHOPRA I. Effect of short-chain organic acids on macromolecular synthesis in Escherichia coli. J Appl Bacteriol 1990 ; 68 : 69-74.
59. RUSSEL JB. Resistance of Streptococcus bovis to acetic acid at low pH: relationship between intracellular pH and anion accumulation. Appl Environ Microbiol 1991 ; 57 : 255-9.
60. ASHARA T, NOMOTO K, SHIMUZU K, et al. Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosacharides. J Appl Microbiol 2001 ; 91 : 985-96.
61. DUNNE C, O'MAHONY L, MURPHY L et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo finding. Am J Clin Nutr 2001 ; 73 (Suppl) : 386S-92S.
62. FALKOW S, ISBERG RR, PORTNOY DA. The interaction of bacteria with mammalian cells. Annu Rev Cell Biol 1992 ; 8 : 333-63.
63. AXELSSON LT, CHUNG TC, DOBROGOSZ WJ, et al. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989 ; 2 : 131-6.
64. MADSEN K, CORNISH A, SOPER P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001 ; 121 : 580-91.
65. BERNET MF, B BRASSART D, NEESER JR, et al. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachments and cell invasion by enterovirulent bacteria. Gut 1994 ; 35 : 483-9.
66. HERIAS MV, HESSLE C, TELEMO E, et al. Immunomodulatory effects of Lactobacillus plantarum colonizing the intestine of gnotobiotic rats. Clin Exp Immunol 1999 ; 116 : 283-90.
67. MACK DR, MICHAIL S, WEI S, et al.. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999 ; 276 : G941-50.
68. GRANATO D, PEROTTI F, MASSEREY I, et al. Cell surface-associated lipotheicoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Appl Environ Microbiol 1999 ; 65 : 1071-7.
69. TUOMOLA EM, SALMINEN SJ. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Int J Food Microbiol 1998 ; 41 : 45-51.
70. OUWEHAND AC, ISOLAURI E, KIRJAVAINEN PV, et al. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact Delbrueckii subsp. Bulgaricus. Lett Appl Microbiol 2000 ; 30 : 10-3.
71. VIGNOLO GM, SURIANI F, HOLDAGO APDR, et al. Antibacterial activity of Lactobacillus strains isolated from dry fermented sausages. J Appl Bacteriol 1993 ; 75 : 344-9.
72. RIGOTHIER MC, MACCANIO J, GAYRAL P. Inhibitory activity of Saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol Res 1994 ; 80 : 10-5.
73. TASTEYRE A, BARC MC, KARJALAINEN T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathogen 2002 ; 32 : 219-25.
74. BRASSART D, SCHIFFRIN E, ROCHAT F, et al. The future of functional foods: scientific basis and future requirements. Lebensmittel Technol 1998 ; 7 : 258-66.
75. COCONNIER MH, BERNET MF, KERNEIS S, et al. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacllus acidophilus strain LB decreases bacterial invasion. FEMS Microbiol Lett 1993 ; 110 : 299-305.
76. WILSON KH, PERINI F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 1988 ; 56 : 2610-4.
77. KAILA M, ISOLAURI E, SOPPI E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992 ; 32 : 141-4.
78. OFFIT PA. Host factors associated with protection against rotavirus diseases: The skies are clearing. J Infect Dis 1996 ; 174 (Suppl) : 59-64.
79. WARD SL. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 1996 ; 174 (Suppl) : S51-8.
80. BUTS JP, BERNASCONI P, VAERMAN JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990 ; 35 : 251-6.
81. BENNO Y, HE F, HOSADA M, et al. Effects of Lactobacillus GG yoghurt on human intestinal microecology in Japanese subjects. Nutr Today 1996 ; 31 (Suppl 6) : 9S-11S.
82. LINK AMSTER H, ROCHAT F, SAUDAN KY, et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994 ; 10 : 55-63.
83. QAMAR A, ABOUDOLA S, WARNY M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001 ; 69 : 2762-5.
84. SCHRIFFIN EJ, BRASSART D, SERVIN AL, et al. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr 2001 ; 73 : 133-4.
85. KORHONEN R, KORPELA R, SAXELIN M, et al. Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. Inflammation 2001 ; 25 : 223-32.
86. PERDIGON G, DE MACIAS ME, Alvarez S, et al. Effect of perorally administered lactobacilli on macrophage activation in mice. Infect Immun 1986 ; 53 : 404-10.
87. MAASSEN CB, HOLTEN-NEELEN C, BALK F, et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000 ; 18 : 2613-23.
88. SHU Q, Qu F, GILL HS. Probiotic treatment using Bifidobacterium lactis HN019 reduces weanling diarrhea associated with rotavirus and Escherichia coli infection in a piglet model. J Pediatr Gastroenterol Nutr 2001 ; 33 : 171-7.
89. MACHADO GAETANO JA, PARAMES MT, BABO MJ, et al. Immunopharmacological effects of Saccharomyces boulardii in healthy volunteers. Int J Immunopharmacol 1986 ; 8 : 245-59.
90. POTHOULAKIS C, KELLY CP, JOSHI MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993 ; 104 : 1108-15.
91. CASTAGLIUOLO I, RIEGLER MF, VALENICK L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999 ; 67 : 302-7.
92. DIAS RS, BAMBIRRA EA, SILVA ME, et al. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Bras J Med Biol Res 1995 ; 28 : 323-5.
93. BRANDAO R, CASTRO IM, BAMBIRRA EA, et al. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 1998 ; 64 : 564-8.